Keryx Biopharmaceuticals (NASDAQ:KERX) Given Daily Coverage Optimism Score of 0.22
News articles about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.0779256299123 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuityâ€™s 37th Annual Growth Conference on … – GuruFocus.com (gurufocus.com)
- Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017 (finance.yahoo.com)
- Keryx Biopharmaceuticals Inc (KERX) Mesa Adaptive MA Sitting Below FAMA – Evergreen Caller (evergreencaller.com)
- Breakfast Technical Briefing on Biotech Stocks — Dynavax Technologies, Keryx Biopharma, La Jolla Pharma, and … – Markets Insider (markets.businessinsider.com)
Keryx Biopharmaceuticals (KERX) traded down 3.4390% during mid-day trading on Monday, reaching $6.7303. The company had a trading volume of 558,184 shares. The firm’s market capitalization is $799.22 million. Keryx Biopharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.38. The stock’s 50-day moving average is $7.14 and its 200 day moving average is $6.10.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.60. The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The firm’s revenue for the quarter was up 62.4% on a year-over-year basis. During the same period last year, the firm earned ($0.42) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post ($1.07) earnings per share for the current fiscal year.
KERX has been the subject of a number of recent research reports. Maxim Group lifted their price objective on Keryx Biopharmaceuticals from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, May 15th. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th. BidaskClub cut Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research report on Wednesday, July 12th. Finally, ValuEngine cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $7.48.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.